PHASE I TRIAL OF ADENOVIRAL VECTOR DELIVERY OF THE HUMAN INTERLEUKIN-12 CDNA

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。乳腺癌是美国女性确诊的主要癌症，1999年估计有176,300例新病例。广泛的长期目标是确定通过瘤内递送表达免疫调节基因的腺病毒载体进行基因治疗是否可以安全耐受，并在转移性乳腺癌患者中产生肿瘤消退和抗肿瘤不团结的有效作用。这项研究的目标之一是调查患者肝脏中的肿瘤是否可以通过基因改变，从而产生一种名为白细胞介素12的物质。这种疗法被称为基因疗法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Breast cancer is the leading cancer diagnosed in women in the United States, with an estimated 176,300 new cases in 1999. The broad long-term objectives are to determine if gene therapy via intratumoral delivery of adenoviral vectors expressing immunomodulatory genes can be safely tolerated and be effective in producing tumor regression and antitumor imunity in patients with metastatic breast cancer. One of the goals of this study is to investigate if the tumor in the patient's liver can be genetically changed so that it produces a substance called interleukin-12. This treatment is called gene therapy.